Performance and compatibility factors to consider when healthcare institutions select molecular diagnostic kits

I. Clarify the Intended Use and Detection Targets

When selecting a molecular diagnostic kit, a medical institution should first verify whether the product's intended use is consistent with the testing items carried out in its own department. Molecular diagnostic kits may be used in different scenarios such as qualitative detection of pathogen nucleic acids, genotyping, drug-resistance mutation detection, and tumor-related gene detection. The design of the detection targets directly affects clinical interpretation; therefore, it is necessary to confirm whether the target range, gene loci, or mutation types covered by the kit meet the general requirements of clinical guidelines or expert consensus. For multiplex detection products, attention should also be paid to whether the targets interfere with one another.

II. Sample Types and Processing Workflow

Different molecular diagnostic kits have explicit requirements for sample types, commonly including throat swabs, nasal swabs, bronchoalveolar lavage fluid, sputum, blood, urine, cervical exfoliated cells, and others. Laboratories need to choose products based on the sample types actually collectible and the patient population. Sample collection tubes, preservation solutions, and transport conditions must also match the kit. If a kit requires a special preservation solution or rapid specimen delivery, and the hospital's existing logistics conditions cannot meet this requirement, testing quality may be affected. Therefore, before procurement, the compatibility between the sample pretreatment workflow and the existing workflow should be fully evaluated.

III. Testing Throughput and Instrument Compatibility

Medical institutions at different levels have different testing throughput requirements. Emergency and outpatient laboratories often hope for a shorter turnaround time, while central laboratories may pay more attention to batch processing capacity. Molecular diagnostic kits need to be compatible with the laboratory's existing nucleic acid extractors, PCR instruments, or integrated detection platforms. Some kits are only suitable for specific instrument models, while others can be used on universal fluorescence PCR platforms. When selecting, the degree of instrument openness, stability of consumable supply, and after-sales service response should also be considered. For departments carrying out point-of-care testing, attention should also be paid to ease of operation and the method of result interpretation.

IV. A Rational View of Performance Parameters

The performance of molecular diagnostic kits is usually described by analytical sensitivity and analytical specificity. Analytical sensitivity reflects the ability of the reagent to detect the lowest target concentration and is commonly expressed as the limit of detection; analytical specificity involves cross-reactivity with non-target pathogens, the human genome, or similar sequences. It should be emphasized that the performance data in the instructions are obtained under specific conditions, and the complexity of actual clinical samples may lead to differences. Medical institutions should take into account the characteristics of their own patient population and, when necessary, conduct localized performance verification rather than relying solely on registration materials.

V. Registration Qualifications and Quality Control

Molecular diagnostic kits sold and used in mainland China should obtain the corresponding medical device registration certificate or filing credential, and medical institutions should verify product qualifications and production license information. The kit packaging should include identifiers such as the registration certificate number, production date, expiration date, and storage conditions. In daily use, the laboratory should also establish an internal quality control plan, using negative quality controls and weak positive quality controls to monitor the status of each batch of tests. If quality control failure occurs, report release should be suspended and the cause should be identified.

VI. Comprehensive Evaluation and Supply Chain Management

In addition to technical performance, the supply stability of molecular diagnostic kits is equally important. Medical institutions may pay attention to the manufacturer's supply cycle, cold-chain transportation capability, and availability of alternative products, so as to avoid affecting clinical testing services due to supply interruption from a single supplier. The procurement department may work together with the clinical laboratory and clinical departments to develop an evaluation form and conduct a comprehensive assessment from multiple dimensions such as compliance qualifications, performance verification, operation training, instrument compatibility, and after-sales service. This is more conducive to selecting molecular diagnostic kits that suit the institution's actual needs.